Title : Tormentic Acid Ameliorates Hepatic Fibrosis in vivo by Inhibiting Glycerophospholipids Metabolism and PI3K/Akt/mTOR and NF-κB Pathways: Based on Transcriptomics and Metabolomics.

Pub. Date : 2022

PMID : 35359829






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Tormentic Acid Ameliorates Hepatic Fibrosis in vivo by Inhibiting Glycerophospholipids Metabolism and PI3K/Akt/mTOR and NF-kappaB Pathways: Based on Transcriptomics and Metabolomics. euscaphic acid AKT serine/threonine kinase 1 Rattus norvegicus
2 In addition, the relevant signaling pathways analysis confirmed that TA inhibited HSCs activation by blocking the PI3K/Akt/mTOR pathway and ameliorated inflammatory injury by inhibiting the NF-kappaB pathway. euscaphic acid AKT serine/threonine kinase 1 Rattus norvegicus
3 In conclusion, TA significantly alleviates liver fibrosis in vivo by inhibiting the glycerophospholipid metabolism pathway and the PI3K/Akt/mTOR and NF-kappaB signaling pathways. euscaphic acid AKT serine/threonine kinase 1 Rattus norvegicus